# EDGAR Filing Document

**Accession Number:** 0001742692
**File Stem:** 0001178913-26-002822
**Filing Date:** 2026-5
**Character Count:** 11422
**Document Hash:** 4098bbcb2079f52285361b05ef593398
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002822.hdr.sgml**: 20260520

**ACCESSION NUMBER**: 0001178913-26-002822

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260520

**FILED AS OF DATE**: 20260520

**DATE AS OF CHANGE**: 20260520

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMode Ltd.
- **CENTRAL INDEX KEY:** 0001742692
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39016
- **FILM NUMBER:** 261001376

**BUSINESS ADDRESS:**
- **STREET 1:** TAVOR BUILDING, SHA?AR YOKNEAM
- **STREET 2:** POB 533
- **CITY:** YOKNEAM
- **STATE:** L3
- **ZIP:** 2069200
- **BUSINESS PHONE:** 972-4-9097470

**MAIL ADDRESS:**
- **STREET 1:** TAVOR BUILDING, SHA?AR YOKNEAM
- **STREET 2:** POB 533
- **CITY:** YOKNEAM
- **STATE:** L3
- **ZIP:** 2069200

**SECURITIES AND EXCHANGE COMMISSION** **<br> WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER<br> PURSUANT TO RULE 13a-16 OR 15d-16 OF<br> THE SECURITIES EXCHANGE ACT OF 1934**

***For the month of May 2026***

------

**INMODE LTD.**

------

(Exact name of registrant as specified in its charter)

**Tavor Building, Sha'ar Yokneam**

**P.O. Box 533**

**Yokneam 2069206 Israel**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F ☒ Form 40-F ☐**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

**Yes ☐ No ☒**

**Appointment of New Director**

On May 19, 2026, the Board of Directors (the "**Board**") of InMode Ltd. (the "**Company**") appointed Dr. Shlomo Nass to the Board, effective immediately. He fills the vacancy left by the previously announced departure of Dr. Michael Anghel on May 5, 2026.

Dr. Nass will serve as a Class II Director, holding office until the annual general meeting of shareholders to be held in 2027. Dr. Nass is an independent director as defined by Nasdaq listing standards. Dr. Nass will serve as Chairman of the Board, as Chairman of the Board's Audit & Investment Committee and as a member of the Board's Compensation, Nominating and Corporate Governance Committee. The Board has determined that Dr. Nass is an "audit committee financial expert" as defined under the rules of the Securities and Exchange Commission and that he meets the financial sophistication requirements under applicable Nasdaq Listing Rules.

Dr. Nass, age 66, currently serves as a senior partner at Firon, an Israeli law firm. He is a member of the Israeli Bar Association and is a Certified Public Accountant in Israel. Dr. Nass is also a Certified Information System Auditor, C.I.S.A (USA). Dr. Nass is a lecturer on Corporate Law at Bar-Ilan University and in the Directors' Training seminar at "Lahav" Executive Education at the Recanati Faculty of Management in Tel-Aviv University.

Dr. Nass will be entitled to the compensation the Company offers its other non-employee directors, in accordance with the Company's Compensation Policy, as in effect from time to time, including annual retainers and equity compensation. Dr. Nass is entitled to indemnification and exculpation and to be an insured under the Company's director and officer liability insurance policy, as are the Company's other executive officers and directors. There is no arrangement or understanding between Dr. Nass and any other person pursuant to which he was appointed as a director. Since the beginning of the last fiscal year of the Company, there have been no related party transactions between the Company and Dr. Nass that would be reportable under Item 404(a) of Regulation S-K.

**Appointment of New Chief Financial Officer**

On May 20, 2026, the Company announced the appointment of Moshe (Moshik) Itzkovich as the Company's new Chief Financial Officer, effective May 19, 2026. As previously disclosed, the Company's prior Chief Financial Officer, Yair Malca, remains engaged as a consultant to ensure a smooth transition.

Mr. Itzkovich, age 41, previously served as the Company's Senior Vice President, Finance, for North America and Europe since January 2026. Prior to that, Mr. Itzkovich served the Company and certain of its wholly owned subsidiaries in various roles, including as Vice President of Finance, North America from January 2022 to December 2025. From August 2018 to December 2021, Mr. Itzkovich served as the Vice President of Finance of Home Skinovations Ltd. Mr. Itzkovich is also a member of the board of directors of the Company's Canadian subsidiary, Invasix Corp. Mr. Itzkovich holds a degree in Accounting and Economics from Tel Aviv University.

Mr. Itzkovich will receive an annual base salary of CAD 500,000 and is entitled to a quarterly discretionary bonus of up to 10% of his annual base salary.

Mr. Itzkovich is entitled to indemnification and exculpation and to be an insured under the Company's director and officer liability insurance policy, as are the Company's other executive officers and directors. There is no arrangement or understanding between Mr. Itzkovich and any other person pursuant to which he was appointed as the Company's Chief Financial Officer. Since the beginning of the last fiscal year of the Company, there have been no related party transactions between the Company and Mr. Itzkovich that would be reportable under Item 404(a) of Regulation S-K.

A copy of the press release announcing the respective appointments of Dr. Nass and Mr. Itzkovich is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| [99.1](exhibit_99-1.htm) | [Press Release dated May 20, 2026](exhibit_99-1.htm) |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **InMode Ltd.** |
|  | By: <u>/s/ Moshe Mizrahy</u> |
|  | Moshe Mizrahy |
| May 20, 2026 | Chief Executive Officer |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**![](image_001.jpg)

**InMode Appoints Dr. Shlomo Nass as Chairman of the Board and**

**Moshik Itzkovich as Chief Financial Officer**

**YOKNEAM, Israel, May 20, 2026 -- InMode Ltd. (Nasdaq: INMD)** ("InMode" or the "Company"), a leading global provider of innovative medical technologies, today announced the appointment of Dr. Shlomo Nass as Chairman of the Company's Board of Directors (the "Board") and Moshik Itzkovich as Chief Financial Officer, effective immediately.

Dr. Nass succeeds Dr. Michael Anghel, who retired earlier this month, and will lead the Board in supporting the Company's long-term strategic growth and governance priorities. Dr. Nass brings decades of expertise in corporate law, accounting, governance, and audit oversight, with extensive experience advising public and private companies on complex regulatory and financial matters.

"We are pleased to welcome Shlomo as Chairman of the Board," said Moshe Mizrahy, Chief Executive Officer. "His deep expertise in corporate governance, financial oversight, and regulatory matters, combined with his extensive leadership experience, will be invaluable as we continue to execute our strategic priorities and drive long-term shareholder value."

"On behalf of the Board and management team, we thank Michael Anghel for his many years of commitment and service to InMode and wish him all the best going forward," Mizrahy concluded.

At the same time, InMode announced the appointment of Moshik Itzkovich as Chief Financial Officer. Moshik has held senior finance roles at InMode and was previously Senior Vice President of Finance. He replaces Yair Malca, who stepped down earlier this month and will serve as a consultant at least through the Company's Annual General Meeting to ensure a smooth transition.

"Having partnered closely with Yair over the last three years, Moshik brings continuity, financial expertise, and strategic insight to this role," said Moshe Mizrahy, Chief Executive Officer. "We are confident he is well positioned to build on our strong financial foundation and support the Company's long-term objectives."

"We thank Yair for his many years of exceptional service. His leadership and contributions have been instrumental to our success, and he played a key role in our transition to a publicly traded Company. He leaves InMode with a very strong balance sheet and solid operational and financial foundations in place for his successor. We are grateful for his lasting impact on the Company," Mizrahy concluded.

**About InMode** 

InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit <u>www.inmodemd.com</u>.

**Forward-Looking Statements**

The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including the actual amount of share repurchases made by the Company, if any. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 10, 2026, and our subsequent public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.

**Investor Relations Contact:**

Miri Segal-Scharia

MS-IR LLC

<u>ir@inmodemd.com</u>